🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07486180
Starting soon Not applicable

The Application of a Novel Endoluminal Robotic System for Colorectal Endoscopic Submucosal Dissection

NCT07486180 · tracked via the Priya Life Science China tracker
Sponsor
Chinese University of Hong Kong
Phase
Not applicable
Started
2026-04
Last updated
2026-03-20

Condition(s) studied

Early Rectal Neoplasms

Investigational drug(s) / intervention(s)

Colorectal Endoscopic Submucosal Dissection (ESD) Using the Intilume Surgical System

Colorectal Endoscopic Submucosal Dissection (ESD) Using the Intilume Surgical System: Colorectal Endoscopic Submucosal Dissection (ESD) Using the Intilume Surgical System by Agilis Robotics

Study summary

Endoluminal surgery through natural orifices is an effective, "incisionless" treatment for benign lesions and early-stage cancers in the urinary tract and gastrointestinal (GI) tract. However, current practice suffers from the use of basic surgical instruments that lack dexterity and the ability to perform effective tissue retraction and provide triangulation. This is illustrated in endoscopic submucosal dissection (ESD) of GI tumors, which is a highly effective technique that has limited widespread adoption due to the exceptionally steep learning curve created by unintuitive and cumbersome instruments. It is suggested that a robotic system may improve en bloc resection capabilities in the GI tract by providing surgeons with dexterous and precise bimanual instrument control. This study aims to evaluate the clinical feasibility and safety of colorectal ESD using a novel endoluminal robotic system - the Intilume System by Agilis Robotics. It is a prospective, single center study consistent with a Stage 1 (Innovation) study described in the Innovation, Development, Exploration, Assessment, Long-term Study (IDEAL) framework. The primary study endpoints are en bloc resection rate and perioperative complications. The secondary study endpoints include R0 resection rate, dissection related metrics, conversion rate, and post-procedure recovery. This study will provide information on the feasibility and safety of the Intilume System developed by Agilis Robotics in performing colorectal ESD. This study may provide pertinent evidence for the continued development of this robotic technology.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with nonpedunculated early rectal neoplasms \>/= 2 cm in size in the rectum (\>/= 3 cm and \</= 18 cm from the anal verge) that are deemed not feasible for en bloc resection with conventional polypectomy or endoscopic mucosal resection (EMR) as judged by two experienced endoscopists * American Society of Anesthesiologists (ASA) grading I-III * Informed consent available Exclusion Criteria: * Presence of endoscopic signs of massive submucosal invasion (including excavated/depressed morphology, Kudo's pit pattern Type V, or Sano's capillary pattern Type IIIB) * Evidence of deep invasion on endorectal ultrasonography * Unfavorable histopathologic features on biopsy (mucinous cancer, poor differentiation, or gross submucosal invasion) * Patients with other synchronous colorectal neoplasms in addition to the index neoplasm that are indicated for surgical resection * Patients with recurrence from previous EMR or ESD * Patients with non-correctable coagulopathy * Patients with contraindications to general anesthesia * Vulnerable population (e.g., mentally disabled, pregnancy.)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Prince of Wales Hospital, The Chinese University of Hong Kong Hong Kong China

More Chinese University of Hong Kong trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07486180 on ClinicalTrials.gov ↗ ← All trials in China